title: Bumadizone calcium dihydrate microspheres compressed tablets for colon targeting: formulation, optimization and in vivo evaluation in rabbits.
abstract: The objective of this study was the development of a colon-targeted microspheres which were compressed into tablets containing the non-steroidal anti-inflammatory bumadizone calcium hemihydrate. [corrected]. A 3(2) full factorial design was adopted for the evaluation of the prepared microspheres. The effect of two independent variables namely polymer type (Eudragit RS100, ethyl cellulose and cellulose acetate butyrate), and drug: polymer ratio (1:1, 9:1 and 18:1) was studied on the entrapment efficiency and in vitro drug release for 12 h. Colon targeting aims to minimize the release of the drug off target area (pH 1.2 and 6.8) and to maximize the release of the drug in target area (pH 7.4). Candidate formulae were compressed into core tablets and colon targeting was achieved using the enzyme-dependent polymer (pectin) as coat in three different concentrations 50, 75 and 90%. Candidate formula F15 (microspheres prepared using BDZ:CAB in a ratio of 18:1 and compressed into tablets using 50% pectin and 50% Avicel in the coat) was able to adequately modulate drug release avoiding drug release in the gastric ambient, and reaching the colonic targeting where 99.7% release was achieved within 12 h following zero-order model. In vivo studies showed that F15 achieved significant decrease in myeloperoxidase activity and inflammation with delayed Tmax (4 h) and lower Cmax (2700 ng/ml) when compared to marketed product.
authors.affiliation: Faculty of Pharmacy, Department of Pharmaceutics, Cairo University , Cairo , Egypt.
authors.forename: Samia A
authors.initials: SA
authors.lastname: Nour
authors.forename: Nevine Shawky
authors.initials: NS
authors.lastname: Abdelmalak
authors.forename: Marianne J
authors.initials: MJ
authors.lastname: Naguib
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D003106:Colon / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry*; D015195:Drug Design; D065546:Drug Liberation; D005260:Female; D008297:Male; D008314:Malonates / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D010316:Particle Size; D011108:Polymers / Q000737:chemistry*; D011817:Rabbits; D013499:Surface Properties; D013608:Tablets, Enteric-Coated
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004337:Drug Carriers; D008314:Malonates; D011108:Polymers; D013608:Tablets, Enteric-Coated; C100233:bumadizone
keywords: Bumadizone calcium; colon targeting; histopathology; microspheres compressed into tablets; myeloperoxidase activity; pharmacokinetic parameters